Anlon Healthcare to hold AGM on Sep 5; approves preferential allotment for acquisitions
Anlon Healthcare Limited will hold its 13th AGM on September 5, 2026. The company will consider audited financial statements for FY26 and approve the issuance of 8.58 crore shares for acquiring stakes in Apiqo Organics (44.94% for ₹116.52 crore) and Bizotic Lifescience (47.41% for ₹36.78 crore). Authorized share capital will be increased from ₹110 crore to ₹130 crore.
The proposed acquisitions of Apiqo Organics and Bizotic Lifescience, along with the significant preferential allotment and increase in authorized share capital, represent major strategic moves for Anlon Healthcare Limited. These actions are expected to have a substantial impact on the company's structure, operations, and future growth.
The announcement details significant corporate actions including acquisitions and capital enhancement, which are generally viewed positively by the market. The clear schedule for the AGM and the strategic nature of the transactions contribute to a positive sentiment.
Anlon Healthcare Limited has announced the date for its 13th Annual General Meeting (AGM), scheduled for Saturday, September 05, 2026, at 11:00 a.m. IST. The meeting will be conducted through video conference and other audio-visual means. The company has also approved the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, for consideration and adoption at the AGM.
Key agenda items for the AGM include the re-appointment of Mr. Punitkumar Rameshbhai Rasadia as Director and the appointment of Mr. Kishan Vinodkumar Raja as a Non-Executive & Independent Director for a term of five years. The company also seeks approval for the remuneration of its Cost Auditor, M/s M. C. Bambhroliya & Associates, for the financial year ending March 31, 2027, with a total remuneration of ₹45,000 plus expenses.
Furthermore, Anlon Healthcare Limited will seek shareholder approval to enhance its authorized share capital from ₹110 crore to ₹130 crore by creating an additional 10 crore equity shares of ₹2 each. This will be followed by an alteration of the capital clause in the Memorandum of Association to reflect the increased share capital.
A significant resolution pertains to the issuance of 8,58,83,617 equity shares on a preferential basis, for a total consideration not exceeding ₹1533.02 crore. This is for the acquisition of 45.16 lakh equity shares (44.94% stake) in Apiqo Organics Private Limited for ₹116.52 crore and 22.99 lakh equity shares (47.41% stake) in Bizotic Lifescience Private Limited for ₹36.78 crore. The shares will be allotted at a price of ₹17.85 per share.
The company also plans to address material related party transactions between Apiqo Organics Private Limited and Anlon Healthcare Limited as per SEBI Listing Regulations.
What to do with a filing like this
Anlon Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anlon Healthcare Limited. Read the original for the full detail.